Abstract WP181: Preprocedual Carotid Plaque Characterization by Duplex Ultrasonography as a Predictor of in-Stent Intimal Restenosis 6 months After Carotid Stenting

Stroke ◽  
2020 ◽  
Vol 51 (Suppl_1) ◽  
Author(s):  
Naoki Takao ◽  
Yuta Hagiwara ◽  
Haruki Ohtsubo ◽  
Yuki Hamada ◽  
Kentaro Tatsuno ◽  
...  
Keyword(s):  
Intimal Hyperplasia ◽  
Carotid Plaque ◽  
Multivariate Logistic Regression Analysis ◽  
Carotid Stenting ◽  
Black Blood ◽  
Carotid Angiography ◽  
Plaque Characterization ◽  
Stent Type ◽  
Closed Cell

Background and Purpose: In-stent intimal restenosis (ISR) caused by neo-intimal hyperplasia generally occurs <24 months after carotid stenting (CAS). Although the real clinical impact of ISR are still unclear, several studies suggested the development of ISR significantly correlated with ipsilateral stroke and death. Also differences in the rate of ISR between open-cell and closed-cell stents have yet to be well evaluated. We aimed to investigate predictors of ISR 6 months after CAS. Methods: We examined 133 patients (mean age of 72.1±8.4 years old) received CAS in a single hospital during 2014 and 2018. Preoperative carotid plaque evaluation was performed by carotid angiography, duplex carotid ultrasonography (CUS), and black-blood carotid artery MRI (BB-MRI). Mean stenosis rate (NASCET) was 71.0±12.3% (44%-100%). Follow-up carotid angiography was performed six months after CAS in all patients according to a predefined protocol. ISR was defined as in-stent intimal hyperplasia more than 50% stenosis based on the NASCET method. Selection of stent type was at the discretion of the treating physician. Predictors of ISR were determined by multivariate logistic regression analysis. Results: Follow-up angiography demonstrated ISR in 33 patients (24.8%). In 44 patients, more than 2 stents were deployed. Univariate analyses demonstrated hypoechoic plaque, 1 mobile plaque with jerry fish sign, complete occlusive or pseudo occlusive lesion, closed-cell stent are significantly associated with ISR (>50%), however no association was observed in traditional risk factors, MRI plaque characterization, and implantation of multiple stents. Multivariate analysis demonstrated low echoic plaque in preoperative CUS (OR4.67; 95%CI, 1.85-11.78) and closed-cell stent (OR 0.378; 95%CI, 0.15-0.97) as significant predictors of ISR. Conclusions: Preprocedual plaque characterization by CUS but not MRI appeared to be useful to predict ISR 6 months after CAS even after adjustment of stent type.

Follow-up outcomes of intracranial aneurysms treated using braided or laser-cut stents with closed-cell design: a propensity score-matched case-controlled comparison

2020 ◽  
pp. neurintsurg-2020-016165
Author(s):  
JeongWook Lim ◽  
Young Dae Cho ◽  
Noah Hong ◽  
Jeongjun Lee ◽  
Dong Hyun Yoo ◽  
...  
Keyword(s):  
Propensity Score ◽  
Intracranial Aneurysms ◽  
Cell Design ◽  
Stent Group ◽  
Stent Type ◽  
Closed Cell ◽  
Matched Case ◽  
The Impact ◽  
Braided Stent

BackgroundThe impact of various stents on patients with intracranial aneurysms who undergo stent-assisted coiling has been debated. We conducted this study to compare follow-up outcomes of coiling procedures involving braided or laser-cut stents with closed-cell design. A propensity score-matched case-controlled analysis was applied.MethodsA total of 413 intracranial aneurysms consecutively coiled using laser-cut (n=245) or braided stents (n=168) in procedures performed between September 2012 and June 2017 were eligible for study. Time-of-flight magnetic resonance angiography, catheter angiography, or both were used to gauge occlusive status after coiling. Recanalization was determined by Raymond classification (complete occlusion vs recanalization). A propensity score-matched analysis was conducted, based on probability of stent type in use.ResultsUltimately, 93 coiled aneurysms (22.5%) showed some recanalization (minor, 51; major, 42) during the follow-up period (mean 21.7±14.5 months). Patient gender (P=0.042), hyperlipidemia (P=0.015), size of aneurysm (P=0.004), neck size (P<0.001), type of aneurysm (P<0.001), and packing density (P=0.024) differed significantly by group. Midterm and cumulative recanalization incidence rates in the braided-stent group were initially lower than those of the laser-cut stent group (P=0.009 and P=0.037, respectively) but they did not differ significantly after 1:1 propensity score matching (midterm OR=0.88, P=0.724; cumulative HR=0.91, P=0.758).ConclusionIn stent-assisted coiling of intracranial aneurysms, laser-cut and braided stent groups produced similar outcomes in follow-up. Consequently, product selection may hinge on suitability for deployment rather than anticipated results.

scholarly journals A Tertiary Cardiology Unit Perspective for Carotid Lesions: Which Lesion and When Intervention

2020 ◽  
Author(s):  
Emre Özdemir ◽  
Muhammed Mücahit Tiryaki ◽  
Nihan Kahya Eren ◽  
Cem Nazlı ◽  
Mehmet Tokaç
Keyword(s):  
Carotid Stenting ◽  
Treatment Modalities ◽  
Common Symptom ◽  
Carotid Angiography ◽  
Common Cause ◽  
Mortality And Morbidity ◽  
Related Data ◽  
Tertiary Center ◽  
The Mean

INTRODUCTION: Stroke is one of the most common cause of mortality and morbidity all over the world, while atherosclerosis is the most common cause of its etiology. For this patients carotid endarterectomy (CEA) and carotid stenting (CAS) are two treatment modalities. In our study, carotid angiography in a tertiary center screened and treatment experiences, methods will present. METHODS: Carotid angiography performed in our hospital between June 2006 and 2018 in a single tertiary cardiology clinic was retrospectively screened and patients were included in the study including CAS, CAE and medical follow-up. The patient's clinical features and procedure-related data were obtained by scanning the patient files. RESULTS: A total of 905 carotid angiography were screened. Critical carotid artery lesions were detected in 476 patients. 49 patients were classified as CAS, 192 patients as CEA, and 235 as medical group. The mean age of the included patients was 66.08±10.53 and the patient population was 74.2% male. The most common comorbidity was coronary artery disease (81.6%) and arterial hypertension (63.3%). The most common symptom was stroke (73.3%). In the CAS group, the rate of stroke was 6.1% in the follow-up period, the rate of stroke in the medical follow-up group was 5.5%, and in the CEA group, the stroke rate was 3.6%. There was a 3.1% mortality in the CEA group. The procedure was completed without any complication in all CAS patients. The mean follow-up period was 1034 days. DISCUSSION AND CONCLUSION: Although CEA is still a class 1 indication despite the improvements in stent and protection devices, CAS can successfully perform in our center as well as in experienced centers.

Abstract 125: Intravascular Ultrasound: A Clinically Useful Tool for Carotid Plaque Characterization

2012 ◽  
Vol 32 (suppl_1) ◽  
Author(s):  
Elizabeth Hitchner ◽  
Mohamed A Zayed ◽  
George Lee ◽  
Weesam Al-Khatib ◽  
Barton Lane ◽  
...  
Keyword(s):  
Carotid Artery ◽  
Intravascular Ultrasound ◽  
Carotid Artery Stenosis ◽  
Carotid Plaque ◽  
Patient Characteristics ◽  
Carotid Stenting ◽  
Artery Stenosis ◽  
Plaque Morphology ◽  
Plaque Characterization ◽  
Plaque Area

OBJECTIVE: Virtual Histology Intravascular Ultrasound (VH™ IVUS) is valuable for estimating minimal lumen diameter (MLD) and plaque characterization. The clinical use of IVUS in the carotid arteries is not well characterized. To evaluate carotid plaque morphology, we performed VH™ IVUS in patients with known carotid artery stenosis. METHODS: From July 2010, patients were prospectively enrolled in an IRB approved study to undergo IVUS prior to an elective carotid stenting procedure. Hospital records were reviewed for co-morbidities, carotid/arch anatomy, preoperative carotid duplex velocity measurements, and incidence of postoperative microemboli. Comparison of pre- and postoperative diffusion-weighted MR images was used to identify microemboli. IVUS-derived MLD and vessel wall plaque characteristics were collected. Spearman correlation was performed between MLD and duplex estimated stenosis, and between plaque characteristics and frequency of postoperative microemboli. RESULTS: 14 patients were enrolled during the study period with carotid artery stenosis (average ICA/CCA ratio 5.5, 64.3% asymptomatic). Major co-morbidities included hyperlipidemia (79%), diabetes (71%), and angina (43%). 57% of patients had type 1 arches, and 50% of patients had heavily calcified irregular carotid plaques. MLD correlated with preoperative duplex ICA/CCA ratio (R2=-0.56,p=0.05), and carotid plaque area correlated with peak systolic and diastolic velocities (R2=-0.55,p=0.05). Although microembolic frequency did not correlate with preoperative patient characteristics, it correlated with IVUS-derived plaque necrotic core area (R2=0.53,p=0.05). CONCLUSION: We demonstrate that periprocedural carotid IVUS is clinically feasible and useful. Preoperative duplex measurements correlated with IVUS MLD confirming the fidelity of the technique. Moreover carotid IVUS demonstrates that patients with necrotic plaque cores have a higher frequency of postoperative microemboli. These findings suggest that carotid IVUS may be helpful to identify patients who are at higher risk of microemboli during carotid artery stenting.

scholarly journals Stent Design, Restenosis and Recurrent Stroke After Carotid Artery Stenting in the International Carotid Stenting Study

Stroke ◽  
2019 ◽  
Vol 50 (11) ◽  
pp. 3013-3020 ◽  
Author(s):  
Mandy D. Müller ◽  
John Gregson ◽  
Dominick J.H. McCabe ◽  
Paul J. Nederkoorn ◽  
H. Bart van der Worp ◽  
...  
Keyword(s):  
Carotid Artery ◽  
Carotid Artery Stenting ◽  
Recurrent Stroke ◽  
Carotid Stenting ◽  
Hazard Ratio ◽  
Stent Design ◽  
Open Cell ◽  
Closed Cell

Background and Purpose— Open-cell carotid artery stents are associated with a higher peri-procedural stroke risk than closed-cell stents. However, the effect of stent design on long-term durability of carotid artery stenting (CAS) is unknown. We compared the medium- to long-term risk of restenosis and ipsilateral stroke between patients treated with open-cell stents versus closed-cell stents in the ICSS (International Carotid Stenting Study). Methods— Patients with symptomatic carotid stenosis were randomized to CAS or endarterectomy and followed with duplex ultrasound for a median of 4.0 years. We analyzed data from patients with completed CAS procedures, known stent design, and available ultrasound follow-up. The primary outcome, moderate or higher restenosis (≥50%) was defined as a peak systolic velocity of >1.3 m/s on ultrasound or occlusion of the treated internal carotid artery and analyzed with interval-censored models. Results— Eight hundred fifty-five patients were allocated to CAS. Seven hundred fourteen patients with completed CAS and known stent design were included in the current analysis. Of these, 352 were treated with open-cell and 362 with closed-cell stents. Moderate or higher restenosis occurred significantly less frequently in patients treated with open-cell (n=113) than closed-cell stents (n=154; 5-year risks were 35.5% versus 46.0%; unadjusted hazard ratio, 0.68; 95% CI, 0.53–0.88). There was no significant difference in the risk of severe restenosis (≥70%) after open-cell stenting (n=27) versus closed-cell stenting (n=43; 5-year risks, 8.6% versus 12.7%; unadjusted hazard ratio, 0.63; 95% CI, 0.37–1.05). The risk of ipsilateral stroke beyond 30 days after treatment was similar with open-cell and closed-cell stents (hazard ratio, 0.78; 95% CI, 0.35–1.75). Conclusions— Moderate or higher restenosis after CAS occurred less frequently in patients treated with open-cell stents than closed-cell stents. However, both stent designs were equally effective at preventing recurrent stroke during follow-up. Clinical Trial Registration— URL: http://www.isrctn.com/ . Unique identifier: ISRCTN25337470.

Patients with “benign” Chiari I malformations require surgical decompression at a low rate

2019 ◽  
Vol 23 (4) ◽  
pp. 498-506 ◽  
Author(s):  
Tofey J. Leon ◽  
Elizabeth N. Kuhn ◽  
Anastasia A. Arynchyna ◽  
Burkely P. Smith ◽  
R. Shane Tubbs ◽  
...  
Keyword(s):  
Surgical Treatment ◽  
Posterior Fossa ◽  
Multivariate Logistic Regression Analysis ◽  
Large Cohort ◽  
Initial Evaluation ◽  
Published Data ◽  
Posterior Fossa Decompression ◽  
Signal Abnormality ◽  
Chiari I

OBJECTIVEThere are sparse published data on the natural history of “benign” Chiari I malformation (CM-I)—i.e., Chiari with minimal or no symptoms at presentation and no imaging evidence of syrinx, hydrocephalus, or spinal cord signal abnormality. The purpose of this study was to review a large cohort of children with benign CM-I and to determine whether these children become symptomatic and require surgical treatment.METHODSPatients were identified from institutional outpatient records using International Classification of Diseases, 9th Revision, diagnosis codes for CM-I from 1996 to 2016. After review of the medical records, patients were excluded if they 1) did not have a diagnosis of CM-I, 2) were not evaluated by a neurosurgeon, 3) had previously undergone posterior fossa decompression, or 4) had imaging evidence of syringomyelia at their first appointment. To include only patients with benign Chiari (without syrinx or classic Chiari symptoms that could prompt immediate intervention), any patient who underwent decompression within 9 months of initial evaluation was excluded. After a detailed chart review, patients were excluded if they had classical Chiari malformation symptoms at presentation. The authors then determined what changes in the clinical picture prompted surgical treatment. Patients were excluded from the multivariate logistic regression analysis if they had missing data such as race and insurance; however, these patients were included in the overall survival analysis.RESULTSA total of 427 patients were included for analysis with a median follow-up duration of 25.5 months (range 0.17–179.1 months) after initial evaluation. Fifteen patients had surgery at a median time of 21.0 months (range 11.3–139.3 months) after initial evaluation. The most common indications for surgery were tussive headache in 5 (33.3%), syringomyelia in 5 (33.3%), and nontussive headache in 5 (33.3%). Using the Kaplan-Meier method, rate of freedom from posterior fossa decompression was 95.8%, 94.1%, and 93.1% at 3, 5, and 10 years, respectively.CONCLUSIONSAmong a large cohort of patients with benign CM-I, progression of imaging abnormalities or symptoms that warrant surgical treatment is infrequent. Therefore, these patients should be managed conservatively. However, clinical follow-up of such individuals is justified, as there is a low, but nonzero, rate of new symptom or syringomyelia development. Future analyses will determine whether imaging or clinical features present at initial evaluation are associated with progression and future need for treatment.

scholarly journals POS0693 EFFICACY AND SAFETY OF BELIMUMAB IN PATIENTS WITH LUPUS NEPHRITIS IN REAL-LIFE SETTING: RESULTS FROM A LARGE, NATIONWIDE, MULTICENTRIC, PROSPECTIVE COHORT

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 594-595
Author(s):  
F. Saccon ◽  
M. Gatto ◽  
M. Zen ◽  
M. Fredi ◽  
F. Regola ◽  
...  
Keyword(s):  
Lupus Erythematosus ◽  
Independent Predictor ◽  
Rescue Therapy ◽  
Real Life ◽  
Multivariate Logistic Regression Analysis ◽  
Class Iii ◽  
Baseline Serum ◽  
Renal Response ◽  
Real Life Setting

Background:LN is still a severe manifestation of Systemic lupus erythematosus (SLE) and multitarget therapy is needed to control the disease especially in refractory cases.Objectives:To evaluate renal response in SLE patients with glomerulonephritis (GN) treated with Belimumab in real-life setting.Methods:Patients with proteinuria >0.5 g/24 h and/or active sediment at baseline enrolled in a multicentre Italian cohort of SLE patients (BeRLiSS study), treated with monthly iv Belimumab 10 mg/kg plus standard of care were considered in this study. Complete renal response (CRR) was defined as proteinuria <0.5 g/24 h, estimated glomerular filtration rate (eGFR)≥90ml/min/1.73m2 and no rescue therapy. Primary efficacy renal response (PERR) was defined as proteinuria ≤0.7 g/24 h, eGFR ≥60ml/min/1.73m2 and no rescue therapy. Prevalence and predictive factors of CRR and PERR at 12 and 24 months after Belimumab initiation were analyzed by multivariate logistic regression analysis.Results:A total of 91 patients were considered in this study, 79 female, mean age 40.51±9.03 years, mean disease duration 12.18±8.15 years, median follow-up time after Belimumab initiation 22 months. Twenty patients had baseline proteinuria ≥0.5 <1 g/day, 17 ≥1 <2 g/day, 13 ≥2 g/day. Belimumab was started at GN onset in 20 (22%) patients and at the time of a renal flare in all other cases. Seventy-five patients underwent a renal biopsy: 1 class I, 4 class II, 14 class III, 47 class IV and 9 class V. Baseline serum creatinine was 82.44±29.26 umol/L; 15 patients showed eGFR<60ml/min/1.73m2 at baseline. Immunosuppresants were taken by 70 (76.9%) patients: 47 micofenolate, 15 azathioprine and 5 ciclosporine. Sixty patients (65.9%) were on antimalarials. During follow-up 34 (37.4%) patients achieved CRR. Among them 5 (14.7%) patients relapsed and 29 (85.3%) patients maintained remission. Mean time to achieved CRR was 9.71±5.91 months.High levels of baseline proteinuria were a negative independent predictor of CRR and PERR at 6 months (OR 0.044 CI95% 0.006-0.320 p=0.002 and OR 0.232 CI95% 0.091-0.596 p=0.002) and 12 months (OR 0.029 CI95% 0.002-0.556 p=0.019 and OR 0.056 CI95% 0.009-0.327 p=0.001). High levels of baseline creatinine were a negative independent predictor of renal response. Renal response at 6 months was a strong predictive factor of renal response at 12 and 24 months.Conclusion:Belimumab is an effective add-on therapy in the treatment of GN in real-life practice setting.Disclosure of Interests:None declared

scholarly journals Cardiac involvement in COVID-19 patients: mid-term follow up by cardiovascular magnetic resonance

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Hui Wang ◽  
Ruili Li ◽  
Zhen Zhou ◽  
Hong Jiang ◽  
Zixu Yan ◽  
...  
Keyword(s):  
Cardiovascular Magnetic Resonance ◽  
Magnetic Resonance ◽  
Cardiac Involvement ◽  
Global Longitudinal Strain ◽  
Cine Imaging ◽  
Black Blood ◽  
Healthy Controls ◽  
Term Outcome ◽  
Post Contrast

Abstract Background Coronavirus disease 2019 (COVID-19) induces myocardial injury, either direct myocarditis or indirect injury due to systemic inflammatory response. Myocardial involvement has been proved to be one of the primary manifestations of COVID-19 infection, according to laboratory test, autopsy, and cardiovascular magnetic resonance (CMR). However, the middle-term outcome of cardiac involvement after the patients were discharged from the hospital is yet unknown. The present study aimed to evaluate mid-term cardiac sequelae in recovered COVID-19 patients by CMR Methods A total of 47 recovered COVID-19 patients were prospectively recruited and underwent CMR examination. The CMR protocol consisted of black blood fat-suppressed T2 weighted imaging, T2 star mapping, left ventricle (LV) cine imaging, pre- and post-contrast T1 mapping, and late gadolinium enhancement (LGE). LGE were assessed in mixed both recovered COVID-19 patients and healthy controls. The LV and right ventricle (RV) function and LV mass were assessed and compared with healthy controls. Results A total of 44 recovered COVID-19 patients and 31 healthy controls were studied. LGE was found in 13 (30%) of COVID-19 patients. All LGE lesions were located in the mid myocardium and/or sub-epicardium with a scattered distribution. Further analysis showed that LGE-positive patients had significantly decreased LV peak global circumferential strain (GCS), RV peak GCS, RV peak global longitudinal strain (GLS) as compared to non-LGE patients (p < 0.05), while no difference was found between the non-LGE patients and healthy controls. Conclusion Myocardium injury existed in 30% of COVID-19 patients. These patients have depressed LV GCS and peak RV strains at the 3-month follow-up. CMR can monitor the COVID-19-induced myocarditis progression, and CMR strain analysis is a sensitive tool to evaluate the recovery of LV and RV dysfunction.

scholarly journals POS0517 A LONGITUDINAL STUDY OF SARCOPENIA, LOCOMOTIVE SYNDROME, AND FRAILTY IN PATIENTS WITH RHEUMATOID ARTHRITIS: FROM THE CHIKARA STUDY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 492.2-492
Author(s):  
K. Mandai ◽  
M. Tada ◽  
Y. Yamada ◽  
T. Koike ◽  
T. Okano ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Multivariate Logistic Regression Analysis ◽  
Locomotive Syndrome ◽  
Chi Squared ◽  
Higher Doses ◽  
Rheumatoid Arthritis Data ◽  
Onset Rate ◽  
New Onset

Background:Rheumatoid arthritis (RA) patients have a high frequency of sarcopenia, and they commonly have reduced physical function. We previously reported that the prevalence of sarcopenia was 28%, that of frailty was 18.9%, and that of pre-frailty was 38.9% in RA patients1,2, and 13.2% of RA patients developed sarcopenia within a year 3.Objectives:To investigate the risk factors for new onset of sarcopenia, locomotive syndrome, and frailty in patients with RA and the course of each disease.Methods:Two-year follow-up data from the rural group of the prospective, observational CHIKARA study were used. Sarcopenia was diagnosed using the criteria of the Asian Working Group for Sarcopenia 2014, locomotive syndrome was diagnosed using locomotive 5, and frailty was diagnosed using the basic checklist. New onset of the disease over the 2-year follow-up period was studied, excluding cases that had the disease at baseline. Improvement was defined as cases with disease at baseline that no longer met the diagnostic criteria after 2 years. Differences in the characteristics of each disease were tested using the Chi-squared test and the paired t-test.Results:The 81 patients with RA (82.7% female) had mean age 66.9±11.5 years, mean DAS28-ESR 2.9±1.2, methotrexate use in 81.5% (with a dose of 9.9±2.7 mg/week), and glucocorticoid (GC) use in 22.2% (with a dose of 3.1±1.7 mg/week). The baseline prevalence was 44.4% for sarcopenia, 35.8% for locomotive syndrome, and 25.9% for frailty, and the new onset rate was 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. Of the patients with each disease at baseline, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty, and of those with each disease at 2 years, 36.1% had sarcopenia, 20.7% had locomotive syndrome, and 33.3% had frailty. The new onset sarcopenia and locomotive syndrome groups had significantly higher rates of GC use (p=0.036, p=0.007, paired t-test) and significantly higher doses (p=0.01, p=0.001, paired t-test) than the groups without new onset sarcopenia and locomotive syndrome. High baseline disease activity was an independent predictor of new onset of locomotive syndrome on multivariate logistic regression analysis (OR=3.21, p=0.015).Conclusion:The new onset rates at 2 years were 4.4% for sarcopenia, 15.4% for locomotive syndrome, and 13.3% for frailty. In the new onset sarcopenia and locomotive syndrome groups, both GC use and dosage were significantly higher.References:[1]Tada M, et al. Matrix metalloprotease 3 is associated with sarcopenia in rheumatoid arthritis - results from the CHIKARA study. Int J Rheum Dis. 2018 Nov;21(11):1962-1969.[2]Tada M, et al. Correlation between frailty and disease activity in patients with rheumatoid arthritis: Data from the CHIKARA study. Geriatr Gerontol Int. 2019 Dec;19(12):1220-1225.[3]Yamada Y, et al. Glucocorticoid use is an independent risk factor for developing sarcopenia in patients with rheumatoid arthritis: from the CHIKARA study. Clin Rheumatol. 2020 Jun;39(6):1757-1764.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document